igen biotech
EspañolEnglish

EPiGen Technology

EPiGen technology parts from scientific results obtained by researchers from La Paz University Hospital, in Madrid. These studies show the potential of a biomarker based on epigenetic mechanisms to predict chemotherapy and radiotherapy response in Non Small Cell Lung Cancer (NSCLC) in advanced stages.  This technology has been licensed by IGEN, implemented at ILAB TECH facilities and currently it can be applied for research under "Research Use Only" mark.

 

IGEN will go beyond and plan to develop a range of easy-to-use kits to effectively detect this biomarker from patient samples and to validate it for clinical use.


C/ Gustavo Fernandez Balbuena nº 11      28002 MADRID (SPAIN)     t: +34 91 510 29 99      f: +34 91 519 13 26      igen@igenbiotech.com      

Diseñado por sitelicon.com